Please assess the completion status of the following clinical trial:

Trial Title: Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary ITP according to The American Society of Hematology (ASH) Guidelines at least 6 months before screening, regardless of splenectomy status~* Age ≥ 1 year and \< 18 years of age~* Refractory to prior ITP therapy, relapsed after at prior ITP therapy, or be ineligible for other therapies. Examples of prior therapy include: corticosteroids, intravenous Immunoglobulin (IVIG), anti-D immunoglobulin, platelet transfusions.~* Platelet count ≤ 30 x10\^9/L or is experiencing uncontrolled bleeding~* Has provided informed consent before any study-specific procedure;~* Adequate hematologic, renal, and liver function during screening:~  * Hemoglobin \> 10.0 g/dL~ * Serum creatinine ≤ 1.5 x the upper limit of normal (ULN)~ * Total serum bilirubin ≤ 1.5 x the ULN~ * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x the ULN~* For the EU, Switzerland and Turkey protocol supplement, subject must agree to a scheduled bone marrow biopsy and aspirate at Year 1 or Year 2 following romiplostim treatment and any unscheduled biopsies if clinically indicated~* For the EU, Switzerland and Turkey protocol supplement, a reticulin grade of 0, 1, 2, or 3 according to the modified Bauermeister grading scale, as assessed by central laboratory from a bone marrow biopsy performed within 1 year prior to planned first dose of romiplostim or consent to a pre-treatment bone marrow biopsy and aspirate prior to planned first dose of romiplostim~Exclusion Criteria:~* History of a bone marrow stem cell disorder (Any abnormal bone marrow findings other than those typical of ITP must be approved by Amgen before a subject may be enrolled)~* Prior bone marrow transplant or peripheral blood progenitor cell transplant~* Active or prior malignancy except non-melanoma skin cancers within the last 5 years~* History of myelodysplastic syndrome~* History of bleeding diathesis~* History of congenital thrombocytopenia~* History of Hepatitis B, Hepatitis C or human immunodeficiency virus (HIV)~* History of systemic lupus erythematosus, Evans syndrome, or autoimmune neutropenia~* History of antiphospholipid antibody syndrome or known positive for lupus anticoagulant~* History of disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura~* History of venous thromboembolism or thrombotic events~* Previous use of romiplostim or previous use of eltrombopag within 4 weeks of enrollment~* Previous use of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), recombinant human thrombopoietin (rHuTPO) or any other platelet producing agent~* Rituximab (for any indication) or 6-mercaptopurine within 8 weeks of enrollment, or anticipated use at any time during the study~* Splenectomy within 4 weeks of the screening visit~* Alkylating agents within 8 weeks before the screening visit or anticipated use during the time of the proposed study~* Vaccinations known to decrease platelet counts within 8 weeks before the screening visit~* Currently enrolled in another investigational device or drug study, or less than 30 days since ending investigational study~* Will have investigational procedures while enrolled on study~* Female subject of child bearing potential (defined as having first menses) not willing to use, in combination with her partner highly effective methods of birth control during treatment and for 1 month after the end of treatment~* Subject is pregnant or breast feeding, or might become pregnant within 1 month after the end of treatment~* Subject has known hypersensitivity to any recombinant Escherichia coli derived product (eg, Infergen®, Neupogen®, somatropin, and Actimmune®)~* Has previously enrolled into this study~* Will not be available for protocol-required study visits or procedures, to the best of the subject's and investigator's knowledge~* Any kind of disorder that, may compromise the subject to give written informed consent and/or to comply with all required study procedures

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Romiplostim (Type: EXPERIMENTAL): Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose was 1 µg/kg titrated in 1 µg/kg increments up to a maximum of 10 µg/kg to reach a target platelet count ≥ 50 x 10⁹/L.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete